Benzeneethanethioicacid,anhydrosulfidewiththiocyanicacid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzeneethanethioicacid,anhydrosulfidewiththiocyanicacid
• 英文别名: S-cyano 2-phenylethanethioate
• 化学式: C₉H₇NOS
• 分子量: 177.22
• InChiKey: XSUCZPWDHFXHBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
  申请人：Crispino Gerard

  公开号：US20050288289A1

  公开（公告）日：2005-12-29

  The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates.

  本发明涉及用于制备吡咯三嗪的中间体，以及制备这种中间体的方法。
• [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ PROTÉINE TYROSINE KINASE
  申请人：METHYLGENE INC

  公开号：WO2009026717A1

  公开（公告）日：2009-03-05

  The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity In Formula (I), the group M is thieno[3,2,b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR).

  该发明涉及式（I）化合物及其用于抑制蛋白酪氨酸激酶活性。在式（I）中，基团M为所示的噻吩[3,2,b]吡啶基团，基团D是一个环或环系统，基团Z、Ar和G如本文所定义。该发明特别涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号传导和HGF受体信号传导。该发明还提供用于治疗细胞增殖性疾病和病症的组合物和方法，例如癌症，并用于治疗眼科疾病，包括老年性黄斑变性（AMD）和糖尿病性视网膜病变（DR）。
• ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF
  申请人：Suda Yoshimitsu

  公开号：US20110034439A1

  公开（公告）日：2011-02-10

  To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. The invention provides an acylthiourea compound represented by formula (I): (wherein each of R 1 and R 2 , which may be the same or different, represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-10 cycloalkyl group, an optionally substituted C 6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 1 and R 2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R 3 represents a C 1-6 alkyl group; and each of R 4 , R 5 , and R 6 , which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 5 and R 6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof.

  提供一种抗肿瘤剂，其表现出优异的c-Met抑制作用，并通过选择性地影响c-Met特异表达的肿瘤细胞来减轻副作用。本发明提供一种由式(I)表示的酰基硫脲化合物：（其中，R1和R2中的每一个，可以相同也可以不同，表示氢原子，可选取代的C1-6烷基，可选取代的C3-10环烷基，可选取代的C6-14芳香烃基，或可选取代的饱和或不饱和杂环基，或R1和R2可以与它们所附着的氮原子一起形成一个可选取代的含氮杂环环；R3表示C1-6烷基；R4、R5和R6中的每一个，可以相同也可以不同，表示氢原子，卤素原子，可选取代的C1-6烷基，C1-6烷氧基，C1-6烷基氨基，可选取代的芳香烃基，或可选取代的饱和或不饱和杂环基，或R5和R6可以与它们所附着的苯环一起形成一个环）。或其盐。
• Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
  申请人：MethylGene Inc.

  公开号：US20130310564A1

  公开（公告）日：2013-11-21

  This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的中间体，例如基于噻唑吡啶的化合物，特别是在工业水平上。
• Fused heterocyclic kinase inhibitors
  申请人：Borzilleri M. Robert

  公开号：US20050288290A1

  公开（公告）日：2005-12-29

  In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

  一般而言，本发明涉及公式I和II的化合物，包括其药学上可接受的盐。本发明的化合物可用作蛋白激酶抑制剂，因此可用于治疗癌症和其他蛋白激酶介导的疾病。